人民财讯1月21日电，千金药业（600479）1月21日公告，国家药品监督管理局批准公司的补血益母丸为 首家中药二级保护品种，该产品适用于气血两虚兼血瘀证产后腹痛。 ...

Group 1 - A total of 2 listed companies had their restricted shares unlocked on January 13, with a total market value of approximately 976 million yuan [1] Group 2 - Specific details of the restricted share unlock include: - Qianjin Pharmaceutical (stock code: 600479) had 24,000 shares released from equity incentive restrictions [2] - Huasheng Lithium Battery (stock code: 688353) had 40.429 million shares released [2]

Group 1 - The first extraordinary general meeting of shareholders for Qianjin Pharmaceutical Co., Ltd. was held on January 12, 2026, at the company's conference room in Zhuzhou, Hunan Province [2] - The meeting was convened by the board of directors and chaired by the chairman, Jian Shun, in compliance with the Company Law and the company's articles of association [2][6] - All 8 current directors attended the meeting, including independent directors who participated via telecommunication [3] Group 2 - There were no resolutions rejected during the meeting, indicating unanimous support for the proposals presented [2] - The meeting's legal proceedings were witnessed by Hunan Qiyuan Law Firm, with lawyers providing a legal opinion confirming the validity of the meeting's procedures and outcomes [5][6] - The meeting's voting procedures and results were deemed legal and effective, ensuring compliance with relevant laws and regulations [6]

Group 1 - The core point of the article is that Qianjin Pharmaceutical has announced the election of Mr. Xu Dawei to the company's 11th Board of Directors during the first extraordinary shareholders' meeting of 2026 [2]

证券代码：600479 证券简称：千金药业 公告编号：2026-002 株洲千金药业股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (一) 股东会召开的时间：2026 年 1 月 12 日 (二) 股东会召开的地点：湖南省株洲市天元区株洲大道 801 号千金药业三楼 会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 开符合《公司法》及《公司章程》的规定。 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 241 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 194,238,512 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 39.4625 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次会议由公司董事会召集，会议由公司董事长蹇顺主持。会议的召集、召 二、 议案审 ...

湖南启元律师事务所 关于 株洲千金药业股份有限公司 2026年第一次临时股东会的 法律意见书 致：株洲千金药业股份有限公司 湖南启元律师事务所（以下简称"本所"）接受株洲千金药业股份有限公司 （以下简称"公司"）的委托，指派本律师出席了公司 2026 年第一次临时股东会 （以下简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人员 及召集人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表 本法律意见。 本律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《株 洲千金药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具 本法律意见书。 本律师声明如下： （一）本律师根据本法律意见书出具日以前已经发生或者存在的事实，严格 履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保 证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 ...

Market Strategy - The market is experiencing fluctuations, with the Shanghai Composite Index slightly rising, achieving a fourteen-day consecutive increase [7] - The overall A-share market saw a 0.19% increase, closing at 6654.1 points, while the Shanghai Composite Index rose by 0.05% to 4085.77 points [7] - The hard technology sector is performing well, with the Sci-Tech 50 Index increasing by 0.99% [7] Industry Dynamics - In 2025, the number of new A-share accounts reached 27.44 million, a 10% increase compared to 2024 [27] - The market for on-site food production in supermarkets in China has surpassed 100 billion yuan, with major supermarket chains achieving a sales share of 10%-20% [29] - A subsidiary of China Communications Construction Company, along with CRRC and MTR, secured over 7 billion Australian dollars in contracts for the Sydney Metro project [31][33] Company Tracking - GF Securities plans to raise capital for its overseas subsidiary through a combination of private placement and convertible bonds, aiming to raise approximately 6.11 billion Hong Kong dollars [34] - Xianle Health obtained 9 invention patents and 2 health food registration certificates in Q4 2025, enhancing its product pipeline [36] - Qianjin Pharmaceutical received drug registration certificates for several products, which will contribute to the company's sustainable development [38]

Group 1: Modern Industrial System Development - The core idea emphasizes the importance of modern industrial systems as the foundation of a modernized economy, with a focus on consolidating and strengthening the real economy [2] - The Ministry of Industry and Information Technology (MIIT) has been advancing new industrialization since the 14th Five-Year Plan, enhancing the overall strength, quality, efficiency, innovation, competitiveness, and risk resistance of the industry [2] - Various regions are accelerating technological innovation and promoting industrial agglomeration and digital transformation, leading to significant progress in building a modern industrial system centered on advanced manufacturing [2][3] Group 2: Innovation and Achievements - China's industrial technology innovation capabilities are steadily improving, with notable achievements in key areas such as stage equipment, photography lenses, high-speed trains, and advanced manufacturing equipment [3] - The first domestically produced light sport aircraft, "Arolora," has received civil aviation certification and has seen sales orders exceed 100 units, with total sales approaching 400 units and over 200,000 flight hours [4] - The number of specialized and innovative small and medium-sized enterprises has increased from less than 40,000 to over 140,000 during the 14th Five-Year Plan, indicating a significant enhancement in the competitiveness of Chinese enterprises [4] Group 3: Industrial Clusters and High-Quality Development - Industrial clusters are crucial for promoting high-quality development and transformation of manufacturing enterprises, with a focus on creating specialized parks and industrial chain ecosystems [5] - The Hunan Medical Device Industrial Park has rapidly developed its medical device industry from scratch in just four years, showcasing the effectiveness of industrial cluster development [5] - The park has improved project approval processes, reducing approval time by 72% and streamlining operations to establish a precise and professional industrial service system [5] Group 4: Digital Transformation in Traditional Industries - Traditional industries such as steel and machinery are accelerating their digital transformation, leveraging artificial intelligence to unlock new potential [7][8] - Shandong Haihua Group has implemented AI-driven strategies to enhance equipment maintenance and inspection, achieving over 95% accuracy in fault identification and a 50% increase in inspection efficiency [7] - The MIIT is promoting digital transformation in manufacturing, establishing 62 digital transformation promotion centers and over 230 exemplary smart factories [10] Group 5: Challenges and Solutions in Digital Transformation - Companies face challenges in recognizing the importance of digital transformation, which is essential for initiating the process [9] - The need for targeted policies to reduce transformation costs and showcase successful case studies is emphasized to motivate enterprises [9] - The MIIT is committed to advancing the digital transformation of the manufacturing sector, focusing on high-level openness and steady development of industrial upgrades [10]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) from the National Medical Products Administration, indicating successful consistency evaluation and enhancing the company's product pipeline, which is beneficial for sustainable development [1] Group 1 - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., have obtained drug registration certificates for three new products [1] - The approval of Dydrogesterone tablets, Baricitinib tablets, and Dapagliflozin tablets signifies that these products have passed the consistency evaluation [1] - The addition of these products to the company's portfolio is expected to enrich its product pipeline and support sustainable growth [1]

Group 1 - The core point of the article is that Qianjin Pharmaceutical has received drug registration certificates for three products from the National Medical Products Administration, indicating a significant regulatory approval milestone for the company [1] Group 2 - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical, received approval for Dydrogesterone tablets, Baricitinib tablets, and Dapagliflozin tablets [1] - The approval of these drugs may enhance the company's product portfolio and market competitiveness in the pharmaceutical industry [1]